There are 2137 resources available
561P - Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours
Presenter: Patricia LoRusso
Session: E-Poster Display
Resources:
Abstract
562P - Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex
Presenter: Analia Azaro Pedrazzoli
Session: E-Poster Display
Resources:
Abstract
563P - First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study
Presenter: Christoph Schliemann
Session: E-Poster Display
Resources:
Abstract
564P - Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours
Presenter: Judy Wang
Session: E-Poster Display
Resources:
Abstract
565P - Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: E-Poster Display
Resources:
Abstract
566P - A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours
Presenter: Michael Carducci
Session: E-Poster Display
Resources:
Abstract
567P - Exposure-response analyses of dabrafenib and trametinib in melanoma patients
Presenter: Steffie Groenland
Session: E-Poster Display
Resources:
Abstract
568P - Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
Presenter: Ilaria Colombo
Session: E-Poster Display
Resources:
Abstract
569P - Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) in combination with anti-CTLA-4 treatment induce complete tumour responses and anti-tumour immune memory in a mouse tumour model
Presenter: Alex Karlsson-Parra
Session: E-Poster Display
Resources:
Abstract
570P - A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC
Presenter: Makoto Nishio
Session: E-Poster Display
Resources:
Abstract